Announcement of the Information Security Management System Certification

ProteoBridge Inc. is pleased to announce that we obtained certification for the international standard JIS Q 27001:2025 (ISO/IEC 27001:2022 + Amd 1:2024), the Information Security Management System (ISMS), as of October 20, 2025.

■ Registration Details

・Standard: JIS Q 27001:2025 (ISO/IEC 27001:2022 + Amd 1:2024)

・Certificate of registration No: JSAI 234

・Initial certification date: 2025/10/20

・The Scope of the Registration:

We offer the following services to customers, such as healthcare institutions,

research organizations, and pharmaceutical companies, using our proprietary

protein array technologies.

1. Analysis of autoantibody data obtained through the use of protein arrays for

autoantibody detection.

2. Preparation, design, and development of protein arrays for autoantibody

detection.

3. Production of comprehensive protein arrays and their application in

autoantibody analysis.

・Construction and maintenance of autoantibody and clinical information

databases.

・Comprehensive management of corporate data, including employee and contract

information.

ProteoBridge provides research testing and contract analysis services utilizing its proprietary protein array technology to medical institutions, research organizations, and pharmaceutical companies. With the acquisition of ISMS certification, our information management framework has been formally recognized by an accredited third-party organization.

Our mission is “to elucidate the causes and mechanisms of autoimmune diseases and to deliver a future filled with hope to people affected by these conditions.” To achieve this mission, we collaborate with partners and researchers worldwide and aim to lead the development of new therapeutics and diagnostics for autoimmune diseases. These activities involve handling diverse and highly sensitive information assets, including research data, collaborative project information, and biological analysis data. Ensuring robust protection of these assets and building a secure research and development foundation are essential to fulfilling our mission.

The successful ISMS certification demonstrates that our information security management framework is properly structured and operated in accordance with international standards. We will continue to strengthen and improve our information security practices to provide a trusted environment for all our stakeholders.

ProteoBridge will remain committed to advancing research and development in the field of autoimmune diseases and contributing to the progress of science and medicine through a highly reliable information management system.

■ About ProteoBridge Inc.

ProteoBridge Inc. is a biotechnology company dedicated to advancing early disease detection and personalized medicine through biomarker research and analysis focused on autoantibodies.

By collaborating with academic institutions and pharmaceutical companies, we strive to develop innovative research assays and analytical technologies in the field of autoimmune diseases.